Skip to the content

pharmaceutical daily

Pharmaceuticals, Biotechnology and Life Sciences

  • HOME
  • Pharma Business
  • About us
    • Media Kit
    • Privacy Policy
  • Contact
March 28, 2018 Off

Glycotope picks Crown Bioscience to work together on immuno-oncology drug discovery pipeline

By Dino Mustafić

Glycotope has chosen Crown Bioscience to work together on immuno-oncology drug discovery pipeline, the subsidiary of Crown Bioscience Internation said…

Broader patient population target opportunity for Shield Therapeutics’s Feraccru in Europe
March 27, 2018 Off

Broader patient population target opportunity for Shield Therapeutics’s Feraccru in Europe

By Dino Mustafić

Shield Therapeutics’s Feraccru can now be used as a treatment of all adults with iron deficiency (ID) as the company…

Novartis sells stake in consumer healthcare JV to GSK for $13.0 billion
March 27, 2018 Off

Novartis sells stake in consumer healthcare JV to GSK for $13.0 billion

By Dino Mustafić

Novartis will sell its 36.5 percent stake in its consumer healthcare joint venture (JV) to GSK for $13.0 billion, it…

Vifor Pharma wants to place its hyperkalaemia treatment in Japan through its partner, Zeria
March 27, 2018 Off

Vifor Pharma wants to place its hyperkalaemia treatment in Japan through its partner, Zeria

By Dino Mustafić

Vifor Pharma Group has granted Japanese company Zeria Pharmaceutical exclusive rights to develop and commercialise Veltassa, its sodium-free potassium binder approved…

March 26, 2018 Off

BMS gets CHMP’s nod for Opdivo as four-week dosing for skin cancer and treated kidney cancer

By Dino Mustafić

Bristol-Myers Squibb said on Monday that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency…

GeNeuro Phase 2 aiming HERVs in multiple sclerosis, first time with benefit shown in clinical trial
March 26, 2018 Off

GeNeuro Phase 2 aiming HERVs in multiple sclerosis, first time with benefit shown in clinical trial

By Dino Mustafić

GeNeuro’s results from the Phase 2b study of its novel therapeutic treatment of multiple sclerosis (MS) showed a significant, consistent positive…

Portola fails to convince EMA that betrixaban is ready for prevention of certain venous thromboembolism in adult patients
March 23, 2018 Off

Portola fails to convince EMA that betrixaban is ready for prevention of certain venous thromboembolism in adult patients

By Dino Mustafić

Portola will need to provide further clarification to the European Medicines Agency (EMA) for making betrixaban available for the prevention the VTE…

Sandoz receives positive CHMP opinion for proposed biosimilar infliximab
March 23, 2018 Off

Sandoz receives positive CHMP opinion for proposed biosimilar infliximab

By Dino Mustafić

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion…

Novartis to seek approval for first SPMS (multiple sclerosis) therapy after the positive Phase III results
March 23, 2018 Off

Novartis to seek approval for first SPMS (multiple sclerosis) therapy after the positive Phase III results

By Dino Mustafić

Novartis could have the first therapy which could delay disability progression secondary progressive multiple sclerosis (SPMS) if it gets the…

GSK’s shingles prevention vaccine approved in Europe and Japan
March 23, 2018 Off

GSK’s shingles prevention vaccine approved in Europe and Japan

By Dino Mustafić

GlaxoSmithKline got the approval for shingles prevention, and post-herpetic neuralgia (PHN) vaccine Shingrix, in Europe, while in Japan it was registered…

Posts pagination

Previous 1 … 3,394 3,395 3,396 … 3,606 Next

JOIN OUR COMMUNITY

Proudly powered by WordPress | Theme: Envo Magazine